Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
US - Pfizer and Wyeth today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The Boards of Directors of both companies have approved the combination.
27 January 2009
2 minute read
